A molecule’s three aliases and the challenge of clinical trial registry tracking

In August 2021, Fujian Suncadia Pharmaceutical filed an investigational new drug (IND) application in Mainland China for a dual glucagon‑like peptide 1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP) agonist. Fujian Suncadia is a wholly-owned subsidiary of Jiangsu Hengrui Medicine, and the filing marked an early step in the development of a molecule that would later attract broader international attention.¹

Cortellis records show how the drug’s identity evolved alongside its development and licensing journey. Initially known as HRS 9531, the code assigned by Fujian Suncadia Pharmaceutical, the molecule was subsequently designated KAI 9531 following the licensing of regional rights to Kailera Therapeutics in May 2024. In March 2026, it received the international nonproprietary name ribupatide.

Same molecule, same data, three distinct labels that made it harder for any simple “company name plus keyword” watchlist to connect the dots. Ripubatide’s journey illustrates the challenges of tracking pharmaceutical assets across markets and stages of development, as changes in sponsors, regional rights and naming conventions can make it harder to connect the different records associated with a program.¹

How HRS-9531 first appeared in clinical trial registries

The first‑in‑human study of HRS‑9531 was registered in December 2021 as a phase 1 trial in healthy participants, with Fujian Suncadia listed as the sponsor and identifiers on both ClinicalTrials.gov and the clinical trial system in Mainland China (NCT05152277 and CTR20212968). Over the next two years, Fujian Suncadia and Hengrui added Phase 1 and Phase 2 studies in type 2 diabetes and obesity, again filed and coded under HRS‑9531.¹

By early 2025, the obesity data from those studies was no longer subtle. A phase 2 trial in overweight and obese subjects showed a mean weight loss of 22.8% at the 8mg dose, with 59% of participants losing at least 20% of their body weight and a manageable safety profile. From a scientific perspective, HRS 9531 had emerged as a promising GLP-1/GIP candidate. Its evolving development history and sponsorship, however, meant that it was not yet widely recognized across international markets.¹

ClinicalTrials.gov, ChiCTR and CDE: what each registry revealed

The way the program appeared in different registries explains why some teams saw this coming and others did not.

ClinicalTrials.gov, run by the U.S. National Library of Medicine, gave broad visibility. It listed the early Fujian Suncadia studies and, later, the pivotal phase 3 obesity trial under identifiers such as NCT05152277 and NCT06396429. In Cortellis Clinical Trials Intelligence analysis, ClinicalTrials.gov is the largest multi‑country registry, with over 590,000 registered studies and roughly 70% coverage across the clinical datasets Cortellis tracks. That breadth comes with low uniqueness: many records are duplicated from other sources, and the mix of early‑phase and late‑stage programs makes it harder to isolate genuinely novel signals.^1,2

Cortellis registry analysis shows that Mainland Chinese registries can provide different perspectives on a drug’s development. The Chinese Clinical Trial Registry (ChiCTR) captures a significant volume of early phase and academic research, including first-in-human studies that may appear there before being registered elsewhere. The Center for Drug Evaluation (CDE), which supports China’s National Medical Products Administration, provides information on later stage development and programs linked to the regulatory process. Together, these sources can help provide a more complete view of a drug’s development journey in Mainland China and beyond.²

Ribupatide illustrates this pattern. Early obesity and diabetes trials were registered under HRS 9531, with Fujian Suncadia as the sponsor, and appeared across both Mainland China and U.S. trial records. Linking these records requires careful attention to registry identifiers, sponsorship and changes in ownership over time. As phase 3 obesity data read out and an application was filed in Mainland China in September 2025, per Cortellis Competitive Intelligence, CDE records provided further insight into the program’s progression toward potential approval. ClinicalTrials.gov remained useful for confirming trial activity and tracking status, while records from Mainland China provided additional context on the program’s regulatory development.^1,2

The May 2024 Hengrui licensing deal and the creation of Kailera

The inflection point for Western companies came on May 16, 2024. On that date, Hengrui licensed international rights to three GLP‑1 candidates, including HRS‑9531, to a new U.S. vehicle called Hercules CM Newco. Per Cortellis Competitive Intelligence, that entity, later renamed Kailera Therapeutics, entered “discovery” status for obesity and type 2 diabetes indications on the same day. Seven months later, Kailera ran the molecule’s first trial outside China, a Phase 1 study in Australia (ACTRN12624001397505) testing KAI-9531 in a non-Asian population — the first time the program appeared under Kailera’s own name.¹

For anyone following Fujian Suncadia across registries, the deal crowned three years of steady clinical build‑out: multiple phase 1 trials, a phase 2 diabetes program that significantly lowered HbA1c and weight, and obesity trials that would soon deliver the 22.8% weight‑loss result. For teams dependent on ClinicalTrials.gov using terms such as “Hengrui” or branded product names, HRS 9531 could be more difficult to identify. The sponsor name differed from that of the parent company, while the molecule was still referenced primarily by its development code.¹

GEMINI-1 results and the global phase 3 program

Once the licensing was in place, Fujian Suncadia and Hengrui moved quickly. The pivotal Chinese obesity study HRS9531‑301, also known as GEMINI‑1, was registered in May 2024 and launched that month, with identifiers CTR20241527 and NCT06396429. The trial enrolled overweight and obese adults and used percent weight change at 48 weeks as the primary endpoint.¹

GEMINI‑1 completed in July 2025 and met its primary endpoint. Topline results showed mean weight loss of up to 17.7%, with 88% of ribupatide‑treated participants achieving at least 5% loss and 44.4% achieving at least 20%. The program also delivered improvements in blood pressure, lipids, insulin resistance and high‑sensitivity C‑reactive protein. Hengrui filed a new drug application for chronic weight management in Mainland China that September.¹

Meanwhile, Kailera’s licensing of rights outside the region became an important part of its financing and development strategy. The company raised capital through private financing rounds before listing on Nasdaq in April 2026, raising approximately $718.8 million to support a global phase 3 program under the ribupatide and KAI 9531 names. The program now includes the KaiNETIC 1, KaiNETIC 2 and KaiNETIC 3 trials in adults with obesity, with and without type 2 diabetes, across the United States, Australia and New Zealand.^{1, 3, 4}

Why multi-registry intelligence surfaces assets sooner

Ribupatide shows what is at stake in how competitive intelligence teams read clinical registries.

Every major step in the program was visible in at least one source: the IND, the first‑in‑human study, the phase 2 diabetes and obesity results, the out‑licensing date, the pivotal obesity trial, the Mainland Chinese new drug application and the global phase 3 launch. ClinicalTrials.gov provided broad confirmation of trial activity and made it useful to track status changes as the asset progressed through international development. Mainland Chinese registries provided visibility into early phase research and regulatory activity earlier in the program’s development, complementing the information available through international trial records.^{1, 2}

This is where multi registry intelligence can add value. By connecting information across registries, organizations can gain a more complete view of an asset’s development, understand regulatory and clinical activity in context, and more effectively track changes in sponsorship, naming and ownership over time. The ribupatide story shows how much of a competitive advantage that understanding can create, years before a headline licensing deal or an initial public offering makes the asset impossible to miss.

Cortellis Clinical Trials Intelligence can help you position your trials for success with data-driven intelligence and analytics spanning 200 countries, 46,000 sponsors and 3,000-plus disease states. Learn more here: Cortellis Clinical Trials Intelligence | Clarivate

Related content:

• What a string of semaglutide biosimilars could mean for Mainland China
• Drugs to Watch 2026: Lilly’s next-generation weight loss drugs
• Winds of change: China’s biopharma innovation 2.0 era
• Rising tides: The surge and thirst for GLP-1s
• The competitive signals hiding in plain sight for biopharma
• One drug, seven names: The hidden complexity of pharmaceutical competitive data

References

1. Clarivate, 2026. Clarivate Registry Analysis. [Online].
2. Clarivate, 2026. s.l.:s.n.
3. Shashikumar, S., 2026. Kailera Therapeutics IPO Raises $718.8M for Obesity Drug Pipeline. [Online]
   Available at: https://xtalks.com/kailera-therapeutics-ipo-raises-718-8m-for-obesity-drug-pipeline-4776/
   [Accessed 6 August 2026].
4. Vinluan, F., 2026. Kailera Plans IPO for Obesity Drug That Could Top Lilly’s Zepbound. [Online]
   Available at: https://medcitynews.com/2026/03/kailera-ipo-obesity-weight-loss-ribupatide-dual-glp-1-gip-receptor-agonist-zepbound-klra/
   [Accessed 6 August 2026].

APAC Asia-Pacific Biopharma Biotech Business Development Clinical trials Dealmaking Endocrinology GLP-1 M&A Metabolic Partnering Pharma Portfolio strategy Real-World Data Regulatory 중국

content_copy Copy link Copied